Kirin-Amgen Inc ("Amgen"), a Californian pharmaceutical company, is the proprietor of EP-B- 0148605 relating to the production of erythropoietin ("EPO") by recombinant DNA technology. EPO is a hormone made in the kidney that stimulates the production of red blood cells by the bone marrow. Amgen had sequenced the EPO gene and its leader sequence, which was essential to any method of making erythropoietin and which was disclosed in their patent.

Will potential licensees and competitors respect a patent and will it survive opposition, revocation or infringement proceedings?

This is a cautionary tale for claimants and defendants alike who either rely upon or are opposed by McKenzie Friends.

Will potential licensees and competitors respect a patent and will it survive opposition, revocation or infringement proceedings?

As the second Trump administration nears the end of its second year, federal agencies are accelerating workplace policy changes across multiple fronts.

This discussion is with particular, but not exclusive, reference to practice in the pharmaceutical industry for claiming new chemical entities, and in particular to the feasibility of defining a genus of compounds that validly covers compounds that have not yet been made and tested.